Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

2003652 citationsJournal Articlebronze Open Access

Authors

Adriano Lazzarin · Istituti di Ricovero e Cura a Carattere Scientifico

Bonaventura Clotet · Hospital Universitari Germans Trias i Pujol

David A. Cooper · National Centre for Clinical Research on Emerging Drugs

Jacques Reynes · Centre Hospitalier Universitaire de Montpellier

Keikawus Arastéh · Auguste-Viktoria-Klinik

Mark Nelson · Chelsea and Westminster Hospital

Christine Katlama

Abstract

The addition of enfuvirtide to an optimized background regimen provided significant viral suppression and immunologic benefit over a 24-week period in HIV-1-infected patients who had previously received multiple antiretroviral drugs.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 348, Issue 22, pp. 2186-2195

DOI: 10.1056/nejmoa035211

Field-Weighted Citation Impact: 39.13